Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
90Y-DOTATOC for somatostatin receptor–positive endocrine neoplasms
2017-002960-42Phase 2Terminated
- Sponsor
- AUSL Romagna
- Start
- Sep 2021
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of yttrium-90 edotreotide in apudoma (NET), endocrine neoplasm (NET) and somatostatin receptor-positive neoplasm, sponsored by AUSL Romagna. Primary endpoint: Disease control. Started Sep 2021; status: terminated.
02
Drugs
yttrium-90 edotreotide
03
Conditions
apudoma (NET)endocrine neoplasm (NET)somatostatin receptor-positive neoplasm
Beyond the preview
Go deeper on 2017-002960-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002960-42.